International Journal of Pharmaceutical Investigation, 2023, 13, 3, 532-537.
Published: July 2023
Type: Original Article
Department of Pharmaceutical Sciences, Jawaharlal Nehru Technological University, Hyderabad, Telangana, INDIA.
Shobha Rani Satla
Center for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, Telangana, INDIA
Anreddy Rama Narsimha Reddy
Department of Pharmacology, Sree Chaitanya Institute of Pharmaceutical Sciences, LMD Colony, Thimmapur, Karimnagar, Telangana, INDIA.
Background: Yohimbine has been suggested as a possible therapy for type 2 diabetes mellitus. Thus, we evaluated antidiabetic activity of yohimbine in Streptozocin (STZ)-induced rats. Materials and Methods: Yohimbine’s anti-diabetic effects were investigated by giving male Wistar rats an injection of Streptozotocin (STZ) to cause diabetes and then analyzing their blood samples. Blood Glucose Levels (BGLs) and glucose tolerance was recorded using an FBG and an OGTT, respectively. Triglyceride, Low-Density Lipoprotein (LDL-c), and High-Density Lipoprotein (HDL-c) levels were determined to examine the impact of yohimbine administration on the lipid profile of diabetic rats. Finally, yohimbine’s impact on pancreatic histological damage due to diabetes was investigated. Results: Overall, our findings imply that yohimbine, an alpha-2 adrenoceptor antagonist, helped diabetic group have better glucose tolerance. Yohimbine-treated mice had lower BGLs and enhanced lipid profiles, with lessened triglyceride and LDL-c levels and improved HDL-c levels. Histopathological analyses showed that the size and density of pancreatic cells had increased and that they had regenerated remarkably. Conclusion: As a result, we can conclude that yohimbine may have therapeutic value for restoring lipid-carbohydrate equilibrium and in repairing diabetes-related pancreatic damage.
Keywords: Yohimbine, Streptozocin, Diabetes, Lipid profile, Pancreas, Histopathology.